Monte Rosa Therapeutics (GLUE) Stock: Buy, Sell, or Hold?
GLUE - Monte Rosa Therapeutics, Inc. Common Stock
$10.50
-0.76 (-6.75%)
▼
5d:
-10.79%
30d:
-26.16%
90d:
-54.84%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GLUE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GLUE is down 10.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GLUE is down 10.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GLUE is currently trading at $10.50, which is considered oversold relative to its 30-day fair value range of $11.91 to $14.27.
Technical Outlook: Technically, GLUE is in a strong downtrend. The price is currently testing key support at $10.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: GLUE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.50 (+153.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GLUE is in a strong downtrend. The price is currently testing key support at $10.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: GLUE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.50 (+153.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.91 -
$14.27
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding GLUE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.7%)
- BULLISH: Trading 153.1% below Wall St target ($28.50)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.91 -
$14.27
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$10.32
Resistance Level
$12.73
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.01
Wall Street Target
$28.50
(+153.1%)
Revenue Growth (YoY)
-61.3%
Share & Embed Analysis
Last updated: October 02, 2026 3:58 PM ET
Data refreshes hourly during market hours. Next update: 4:58 PM
Data refreshes hourly during market hours. Next update: 4:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLUE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Philip Nickson
SELL
5845 shares
2026-04-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
Advanced GLUE Option Strategies
Professional options setups generated by AI based on today's GLUE price and gamma walls.
